Optics.org
Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
News
Menu
Business News

Syneron to pay Palomar $31M in patent settlement

16 Sep 2011

Israel-based Syneron and Palomar settled the case just three weeks before it was due to go before a Massachusetts court.

Syneron has agreed to pay Palomar Medical Technologies $31 million in cash and a new royalty agreement to settle a long-running dispute between the two companies over the sale of laser-based systems for hair removal treatment. The case had been due to go before a Massachusetts Court on October 3 before the two parties agreed the settlement.

Palomar agreed to grant Syneron and its subsidiary Candela – which Syneron acquired after the legal dispute began – a non-exclusive worldwide license for professional laser and lamp-based hair removal systems that Palomar had claimed infringed US patents 5,735,844 and 5,595,568.

Syneron must pay Palomar the $31 million by September 19 under that first part of the agreement, while under the terms of a second settlement it will also pay a royalty on future sales of similar home-use systems sold in the US. That basic royalty will be 5%, rising to 6.5% and 7.5% if Syneron reaches certain undisclosed sales milestones.

Palomar had initially licensed the technology from the Massachusetts-based General Hospital Corporation, and will pay GHC 40% of all the payments that it receives from Syneron through the settlement.

Describing the agreement as “mutually beneficial”, Syneron CEO Louis Scafuri said that the company had a strong balance sheet, and that the paid-up license would represent a positive utilization of the cash it has available. According to its most recent set of financial results, Syneron held $63 million in cash and equivalents as of June 30, as well as $16.5 million in short-term bank deposits and a further $118.3 million in liquid marketable securities.

Fast-growing application
According to Palomar CEO Joseph Caruso, hair removal applications have become one of the fastest-growing applications in the medical sector since it first launched a high-power laser system for the application back in 1997, and “the most popular cosmetic light-based procedure performed today”.

In May, Judge Rya Zobel ruled in the Massachusetts District Court in Boston that all but one of Palomar’s twelve initial claims were invalid – in what had appeared to be a significant victory for Candela and its parent firm. The one remaining claim had centered on the manner in which laser light was focused onto a patient’s skin – Candela products had used a convex lens to do this.

And it appears that the strength of that claim was sufficient for Syneron to agree an out-of-court deal. Commenting in a statement issued after the settlement agreement, Palomar’s general counsel Patricia Davis warned: “Licensing these patents to Candela and Syneron further substantiates the strength of these patents. Palomar intends to continue its strategy of vigorously enforcing our [sic] patent position.”

CEO Caruso added: “Our intellectual property strategy has proved to be a valuable asset for our shareholders and we will continue to focus on expanding our intellectual property in the future.”

BRD Optical Co., LtdPhoton Engineering, LLCAlluxaInfraTec GmbHAVANTES BVEKSMA OPTICSSACHER LASERTECHNIK GMBH
Copyright © 2019 SPIE EuropeDesigned by Kestrel Web Services